Skip to content

Effect of topical tranexamic acid in control of urinary bleeding

Effect of topical tranexamic acid in control of lower urinary system bleeding in emergency department

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014072118545N1
Enrollment
50
Registered
2015-02-25
Start date
2014-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematuria. Unspecified haematuria

Interventions

Intervention 1: For intervention group, We will administer 500 mg tranexamic acid (500mg/5cc, Tranexip, Caspiantamin Drug Group, Iran) in 500cc N/S for bladder irrigation. Intervention 2: For control
Treatment - Drugs
Placebo
For intervention group, We will administer 500 mg tranexamic acid (500mg/5cc, Tranexip, Caspiantamin Drug Group, Iran) in 500cc N/S for bladder irrigation.
For control group, we will use 500 cc N/S with 10 cc pure water as placebo for bladder irrigation.

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : (patient over 40 years old; lower urinary system bleeding like clot or fresh blood). Exclusion criteria : (pregnancy; lactation; history of thrombosis or thromboemboli; coagulopathy; history of myocardial infarction or ischemic stroke; renal failure; urinary tract infarction; disagreement to contribute to research)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Haematuria. Timepoint: 0,1,3, and 24 hours. Method of measurement: Urinary test tape.

Secondary

MeasureTime frame
Haemoglobin. Timepoint: 0, 6, and 24 hours. Method of measurement: CBC Analysis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Hossein Ojaghi Haghighi

Tabriz University of Medical Science

haghighis@tbzmed.ac.ir+98 41 3335 2078

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026